Daniel Schneiderman

Insider Reports History

Entity
Individual
Location
760 Parkside Ave. Suite 304, Suite 207, Brooklyn, NY
Signature
/s/ Daniel Schneiderman
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Daniel Schneiderman:

Stock Role Class Num Shares Value Price $ Report Date Ownership
First Wave BioPharma, Inc. CHIEF FINANCIAL OFFICER Stock option (right to buy) 10K Jan 3, 2022 Direct
Pasithea Therapeutics Corp. Chief Financial Officer Stock Option (right to buy) 5.93K Mar 1, 2024 Direct

Insider Reports Filed by Daniel Schneiderman

Symbol Company Period Transactions Value $ Form Type Date Filed Role
KTTA Pasithea Therapeutics Corp. Mar 1, 2024 2 $0 4/A Apr 5, 2024 Chief Financial Officer
KTTA Pasithea Therapeutics Corp. Mar 1, 2024 2 $0 4 Mar 1, 2024 Chief Financial Officer
KTTA Pasithea Therapeutics Corp. Oct 11, 2022 1 $0 4 Oct 12, 2022 Chief Financial Officer
KTTA Pasithea Therapeutics Corp. Aug 12, 2022 0 $0 3 Aug 15, 2022 Interim Chief Accting Officer
FWBI First Wave BioPharma, Inc. Jan 3, 2022 1 $0 4 Jan 3, 2022 CHIEF FINANCIAL OFFICER
FWBI AzurRx BioPharma, Inc. Jun 30, 2021 4 $0 4 Jul 2, 2021 CHIEF FINANCIAL OFFICER